TIS tissue therapies limited

Hi Neo.I did some calculations a while back but they were pretty...

  1. 1,057 Posts.
    Hi Neo.

    I did some calculations a while back but they were pretty questionable. I would assume at least 30% of sales will fall to the bottom line (npat) where they are earning around 150m pa. That's consistent with other products. Scale will certainly help improve margins considering fixed costs for marketing, sales, etc.

    Watch this one carefully though. Lots of plans, not much cash. I predict a small cr in q1 next year followed by a large cr about 12 to 15 months thereafter (post market entry in the EU and therefore at higher prices).

    Very good prospects long term but a challenging year ahead I suspect.

    Just my thoughts.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.